Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 581,329 | 595,275 | 596,415 | 537,538 | 505,344 |
| Cost of Goods | 128,041 | 130,619 | 135,472 | 146,644 | 116,288 |
| Gross Profit | 453,288 | 464,656 | 460,943 | 390,894 | 389,056 |
| Operating Expenses | 422,804 | 399,709 | 399,011 | 404,626 | 391,761 |
| Operating Income | 30,525 | 65,566 | 62,404 | -13,088 | -2,417 |
| Interest Expense | 3,779 | 3,755 | 3,703 | 3,626 | 4,679 |
| Other Income | 14,923 | 8,999 | -1,944 | -844 | 5,192 |
| Pre-tax Income | 41,669 | 70,810 | 56,757 | -17,558 | -1,904 |
| Income Tax | 1,291 | 14,770 | 5,905 | -17,309 | 4,748 |
| Net Income Continuous | 40,378 | 56,040 | 50,852 | -249 | -6,652 |
| Net Income | $40,378 | $56,040 | $50,852 | $-249 | $-6,652 |
| EPS Basic Total Ops | 0.21 | 0.30 | 0.27 | -0.01 | -0.04 |
| EPS Basic Continuous Ops | 0.21 | 0.30 | 0.27 | -0.01 | -0.04 |
| EPS Diluted Total Ops | 0.21 | 0.29 | 0.27 | 0.01 | -0.04 |
| EPS Diluted Continuous Ops | 0.21 | 0.29 | 0.26 | 0.02 | -0.04 |
| EBITDA(a) | $53,962 | $88,422 | $86,855 | $10,767 | $23,056 |